Report / Business
Published by NOISE
FDA approves pancreatic cancer pill that nearly doubles average survival
From Evening NOISE.
The FDA approved daraxonrasib, also known as Rasonque, a daily tablet developed by Revolution Medicines for pancreatic cancer. The Washington Post reports that clinical trials found the drug nearly doubled average survival compared with chemotherapy, potentially changing treatment for a cancer with a historically poor prognosis.
Saved versions
These dates record changes to NOISE’s copy. They are not event dates.